Celia Espino Lazo
Family · Phoenix, AZNPI 1427720796
Payments from drug & device makers
Across 264 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1K
- AbbVie$966
- Pfizer$382
- UCB, Inc.$306
- Harmony Biosciences LLC$234
- ZOLL Respicardia, Inc.$215
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,33190%
- Education$48010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 28 | $1,135 |
| AbbVie | 87 | $966 |
| Pfizer | 22 | $382 |
| UCB, Inc. | 21 | $306 |
| Harmony Biosciences LLC | 12 | $234 |
| ZOLL Respicardia, Inc. | 15 | $215 |
| Axsome Therapeutics, Inc. | 13 | $172 |
| AstraZeneca | 6 | $161 |
| Lilly USA, LLC | 7 | $119 |
| Lundbeck LLC | 5 | $118 |
| Biogen | 6 | $116 |
| Amneal Pharmaceuticals LLC | 5 | $114 |
| SK Life Science, Inc. | 4 | $107 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $103 |
| Novartis | 4 | $83 |
| Argenx US, Inc. | 3 | $78 |
| Bristol Myers Squibb | 4 | $62 |
| Eisai Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Medtronic | 2 | $47 |
| Impel Pharmaceuticals LLC | 1 | $30 |
| GE HealthCare | 1 | $23 |
| Globus Medical | 1 | $22 |
| Boston Scientific | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| 3b Medical, Inc. | 1 | $11 |
How this compares
$4,811 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 14 | $18,744 |
| Gabapentin | 56 | $590 |
| Donepezil Hcl | 32 | $315 |
| Memantine Hcl | 14 | $254 |
| Amitriptyline Hcl | 18 | $154 |
| Zolpidem Tartrate | 21 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $966 | $18,74414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.